A first-in-human Phase 1 study of a mutant KRAS peptide vaccine (mKRAS-VAX) reported safety and durable immune activity in high-risk pancreatic cancer cohorts. Investigators enrolled 20 individuals with hereditary pancreatic ductal adenocarcinoma predisposition and a radiographic pancreatic abnormality under NCT05013216. Adverse events were grade 1–2, while 18 of 20 participants (90%) generated significant mutant KRAS-specific T-cell responses. Using longitudinal TCR sequencing, the team reported persistence of vaccine-induced mKRAS-specific clonotypes for up to two years, with a median follow-up of 16.5 months. Importantly, no participants developed pancreatic ductal adenocarcinoma during the follow-up window, supporting advancement of mKRAS-targeted vaccination as an interception strategy rather than treatment after diagnosis.